GUELI, ANGELA
 Distribuzione geografica
Continente #
NA - Nord America 179
EU - Europa 98
AS - Asia 56
AF - Africa 1
Totale 334
Nazione #
US - Stati Uniti d'America 179
CN - Cina 42
AT - Austria 34
FR - Francia 16
FI - Finlandia 15
IE - Irlanda 15
SE - Svezia 8
KR - Corea 6
IT - Italia 4
SG - Singapore 4
DE - Germania 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
GR - Grecia 1
IL - Israele 1
JP - Giappone 1
RO - Romania 1
SN - Senegal 1
VN - Vietnam 1
Totale 334
Città #
Chandler 54
Beijing 35
Vienna 34
Dublin 15
Villeurbanne 15
Dearborn 12
Medford 11
Houston 6
Princeton 6
Woodbridge 4
Boardman 2
Nanchang 2
Naples 2
New York 2
Norwalk 2
Nutley 2
Singapore 2
Torino 2
Wilmington 2
Ashburn 1
Chicago 1
Dong Ket 1
Falls Church 1
Fuzhou 1
Guangzhou 1
Hebei 1
Jacksonville 1
Kunming 1
Odesa 1
Philadelphia 1
Ramat Gan 1
San Mateo 1
Sharjah 1
Tokyo 1
Washington 1
Wuhan 1
Totale 227
Nome #
Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. 67
null 64
Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case repor 57
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 54
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival 49
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma 40
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 17
Totale 348
Categoria #
all - tutte 1.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.280


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 0 0 7 1 9 9 1 0 7 3 0
2020/202110 2 0 0 1 1 1 0 0 1 1 1 2
2021/202242 0 0 0 1 0 0 3 4 0 2 10 22
2022/2023109 16 13 5 10 11 16 5 10 12 2 4 5
2023/202426 3 13 2 0 1 3 0 0 0 0 1 3
Totale 348